XML 29 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisition of Vilebrequin (Tables)
 9 Months Ended
Oct. 31, 2012
Acquisition of Vilebrequin [Abstract]  
Unaudited pro forma information of results of operations

The following unaudited pro forma information presents the results of operations of the Company as if the Vilebrequin acquisition had taken place on February 1, 2011:

 

                                 
    Three Months Ended
October 31,		     Nine Months Ended
October 31,		  
    2012     2011     2012     2011  
    (In thousands, except per share amounts)  

Net sales

   $ 552,275     $ 526,442     $ 1,059,507     $ 984,983  

Net income

     49,389       45,496       51,035       48,324  

Net income per share:

                                

Basic

   $ 2.46     $ 2.29     $ 2.56     $ 2.44  

Diluted

   $ 2.42     $ 2.26     $ 2.51     $ 2.39  
Components of the preliminary purchase price allocation for the acquisition

The following table (in thousands) summarizes the components of the preliminary purchase price allocation for the acquisition of Vilebrequin:

 

         

Purchase price:

        

Cash paid

   $ 87,573  

Notes issued

     18,633  

Fair value of contingent consideration

     5,452  
   

 

 

  
    $ 111,658  
   

 

 

  

Allocation:

        

Current assets

   $ 25,793  

Property, plant and equipment

     5,725  

Identifiable intangible assets

     68,847  

Other non-current assets, net

     6,208  

Assumed liabilities

     (12,938 ) 

Deferred income taxes

     (13,020 ) 

Goodwill

     31,043  
   

 

 

  
    $ 111,658